Kiovig (Human Normal Immunoglobulin)

Human Normal Immunoglobulin supplies a broad spectrum of IgG antibodies that bind to pathogens, neutralise toxins and promote opsonisation. The Fc portion of IgG interacts with immune cells, modulating complement activation, cytokine release and auto‑antibody activity, thereby delivering passive immunity and immune regulation.

The dose of Kiovig is individualized. A qualified prescriber determines the appropriate amount, infusion rate and treatment schedule based on the patient’s weight, IgG level, clinical condition and response to therapy. No fixed regimen is provided here.

Safety data for Kiovig in pregnancy and lactation are limited. The decision to use it should be made by a healthcare professional after weighing potential benefits against unknown risks to the fetus or infant. Consultation with a specialist is recommended.

To request Kiovig, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, cold‑chain shipping details and any necessary import documentation.

Kiovig is a high‑purity, EU‑sourced IVIG preparation with a standard IgG profile. Compared with other IVIG brands, it offers similar efficacy for IgG replacement while meeting stringent European manufacturing standards. Choice among products often depends on availability, cost, specific formulation tolerability and institutional preference.

Kiovig must be stored refrigerated at 2 °C to 8 °C. Keep it in the original container, protect from light, and avoid freezing or shaking the solution. If temperature excursions occur, discard the product according to the manufacturer’s guidelines.

Kiovig is given as an intravenous infusion. The healthcare professional prepares the solution according to aseptic technique, selects an appropriate infusion set, and administers it over a period that may range from 30 minutes to several hours, depending on the prescribed dose and patient tolerance.

Serious adverse events include anaphylaxis, thromboembolic complications, acute renal failure, aseptic meningitis, hemolytic anemia and severe thrombocytopenia. Patients should be monitored closely during and after infusion, and any signs of these reactions require immediate medical attention.

Kiovig is contraindicated in individuals with a known severe IgA deficiency who have anti‑IgA antibodies, as they are at high risk for anaphylactic reactions. It should also be avoided in patients with a history of severe hypersensitivity to immunoglobulin products.